Skip to main content
Eutilex Co.,Ltd. logo

Eutilex Co.,Ltd. — Investor Relations & Filings

Ticker · 263050 ISIN · KR7263050007 KO Manufacturing
Open in API
Filings indexed 410 across all filing types
Latest filing 2026-05-18 Regulatory Filings
Country KR South Korea
Listing KO 263050

About Eutilex Co.,Ltd.

https://www.eutilex.com/en/

Eutilex Co., Ltd. is a biotechnology company focused on the research and development of immunotherapeutics for cancers and autoimmune diseases. The company's core approach involves selecting targets that enhance or suppress human immune responses. Its pipeline is centered on three primary technology platforms: T-cell therapy, antibody therapy, and CAR-T cell therapy. Key development programs include adoptive T-cell therapies, such as those based on 4-1BB cytotoxic T lymphocytes (CTL), and various immunomodulatory antibody therapeutics designed to treat a range of incurable diseases.

Recent filings

Filing Released Lang Actions
주권매매거래정지기간변경 (상장폐지 사유 발생)
Regulatory Filings Classification · 90% confidence The document is a regulatory exchange announcement in Korean regarding the change of the trading suspension period for a listed stock under KOSDAQ rules. It does not constitute an actual financial report or delisting notice per se, but is a compliance/regulatory filing. Therefore it falls under the fallback category ‘Regulatory Filings’ (RNS).
2026-05-18 Korean
기타시장안내 (기업심사위원회 개최 결과 안내)
Delisting Announcement Classification · 90% confidence The document is an official announcement regarding the outcome of a corporate review committee’s decision to delist the company’s shares from the KOSDAQ market and outlines the delisting process and objection period. This matches the definition of a Delisting Announcement (DLST).
2026-05-18 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 98% confidence The document is titled “분기보고서” for the period 2026-01-01 to 2026-03-31 (the 12th fiscal term) and contains full financial statements, detailed business descriptions, risk management tables, and notes. It is a comprehensive interim/quarterly report filed with the Financial Supervisory Service and Korea Exchange, not merely an announcement. Therefore, it matches the definition of an Interim/Quarterly Report. Q1 2026
2026-05-14 Korean
주권매매거래정지기간변경 (개선기간 부여)
Regulatory Filings Classification · 75% confidence The document is an official announcement regarding a change in the trading suspension period for the company’s shares under KOSDAQ listing rules. It does not present financial results, governance materials, or details of a specific report, nor is it a notice of a dividend, AGM materials, or share issuance. It is a regulatory announcement related to listing suspension but not a full delisting notice. Therefore, it falls under the generic “Regulatory Filings” category (RNS).
2026-04-21 Korean
기타시장안내 (상장폐지 관련 이의신청서 접수 및 개선기간 부여)
Delisting Announcement Classification · 90% confidence The document is a Korean stock exchange market notice (“기타시장안내”) relating to a delisting proceeding. It repeatedly mentions ‘상장폐지’ (delisting) due to auditor’s disclaimer of opinion and details the objection submission and granted improvement period per KOSDAQ rules. This matches the definition of a Delisting Announcement (Code: DLST).
2026-04-17 Korean
기타시장안내 (개선계획서 제출)
Delisting Announcement Classification · 75% confidence The document is a Korean exchange notice informing that the company (유틸렉스) has submitted an improvement plan after being designated for a listing eligibility review and describing the subsequent steps toward possible delisting. This clearly falls under a delisting announcement rather than a financial report, management change, or other category.
2026-04-16 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.